Drug intelligence / Profile preview

doxorubicin + docetaxel + tamoxifen + cyclophosphamide

Development stage: Unknown
Lead developer: Farmitalia
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

A combination chemotherapy and hormonal therapy regimen used in the treatment of breast cancer. This regimen typically consists of doxorubicin (an anthracycline), docetaxel (a taxane), cyclophosphamide (an alkylating agent), and tamoxifen (a selective estrogen receptor modulator). The drugs may be administered sequentially or in specific combinations, with tamoxifen often given after completion of chemotherapy for hormone receptor-positive disease. This combination has shown efficacy in both early-stage and metastatic breast cancer settings.

Targets

TOP2A (DNA topoisomerase II)DNAESR2 (ERβ)ESR1 (ERα)

Beyond the preview

Go deeper on doxorubicin + docetaxel + tamoxifen + cyclophosphamide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on doxorubicin + docetaxel + tamoxifen + cyclophosphamide.

Explore the full profile